BG
MRNA icon

Bellevue Group’s Moderna MRNA Stock Holding History

Bellevue Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,711
Closed -$227K – 180
2025
Q4 		$227K Sell
7,711
-1,630
-17% -$44.3K ﹤0.01% 151
2025
Q3 		$241K Sell
9,341
-1,229,327
-99% -$34.3M 0.01% 131
2025
Q2 		$34.2M Sell
1,238,668
-279,454
-18% -$7.36M 0.75% 34
2025
Q1 		$43M Sell
1,518,122
-82,755
-5% -$2.94M 0.96% 25
2024
Q4 		$66.6M Buy
1,600,877
+41
+0% +$1.96K 1.28% 23
2024
Q3 		$107M Buy
1,600,836
+37,101
+2% +$3.41M 1.73% 15
2024
Q2 		$186M Sell
1,563,735
-147,354
-9% -$18.6M 3.02% 10
2024
Q1 		$182M Sell
1,711,089
-197,331
-10% -$19.9M 2.78% 8
2023
Q4 		$190M Buy
1,908,420
+413,095
+28% +$34.7M 2.9% 7
2023
Q3 		$154M Sell
1,495,325
-29,734
-2% -$3.32M 2.49% 8
2023
Q2 		$185M Sell
1,525,059
-26,647
-2% -$3.55M 2.64% 7
2023
Q1 		$238M Sell
1,551,706
-30,622
-2% -$5.05M 3.46% 6
2022
Q4 		$284M Buy
1,582,328
+22,527
+1% +$3.68M 3.77% 5
2022
Q3 		$184M Sell
1,559,801
-17,550
-1% -$2.66M 2.65% 6
2022
Q2 		$225M Sell
1,577,351
-61,998
-4% -$8.86M 3.19% 5
2022
Q1 		$282M Sell
1,639,349
-69,900
-4% -$11.8M 3.28% 5
2021
Q4 		$434M Sell
1,709,249
-18,100
-1% -$5.29M 4.47% 1
2021
Q3 		$665M Sell
1,727,349
-814,951
-32% -$301M 6.75% 1
2021
Q2 		$597M Sell
2,542,300
-267,650
-10% -$47.8M 5.83% 1
2021
Q1 		$368M Sell
2,809,950
-136,963
-5% -$19.8M 3.89% 2
2020
Q4 		$308M Sell
2,946,913
-395,037
-12% -$40M 3.53% 3
2020
Q3 		$236M Sell
3,341,950
-3,000
-0.1% -$209K 3.27% 6
2020
Q2 		$215M Sell
3,344,950
-605,231
-15% -$33.1M 3.04% 9
2020
Q1 		$118M Sell
3,950,181
-984,900
-20% -$22.7M 2.29% 11
2019
Q4 		$96.5M Buy
4,935,081
+91,000
+2% +$1.61M 1.53% 16
2019
Q3 		$77.1M Buy
4,844,081
+119,835
+3% +$1.77M 1.43% 19
2019
Q2 		$69.2M Buy
+4,724,246
New +$101M 1.18% 27

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group's MRNA Position: Q1 2026 in Review

Bellevue Group sold out of Moderna (MRNA) in Q1 2026, closing a stake of 7,711 shares — an estimated $227K sold.

Bellevue Group first reported a position in MRNA in Q2 2019 and held it in 27 quarters. The position peaked at $665M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Bellevue Group reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 7,711 Moderna shares in Q1 2026, an estimated $227K.
  • Bellevue Group first reported a position in Moderna in Q2 2019 and held it in 27 quarters.
  • Bellevue Group's Moderna position peaked at $665M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.